Journal of Clinical Oncology
Articles in this Issue
HPV vaccination initiation and completion among sexual minority women in California.
e22573 Background: Human papillomavirus (HPV) is the most common sexually transmitted infection and a known cause of cervi...
Preliminary observation of growth and pubertal development following CAR-T cell therapy for children with systemic lupus erythematosus.
e14516 Background: Prolonged glucocorticoid and immunosuppressive therapy in systemic lupus erythematosus (SLE) children c...
EMBARK: Testosterone recovery to >250 ng/dL following treatment suspension.
5088 Background: The phase 3 EMBARK trial demonstrated significantly longer metastasis-free survival and overall survival...
Contemporary outcomes and treatment patterns in neuroendocrine carcinoma of the breast: A population-based SEER analysis.
e12758 Background: Neuroendocrine carcinoma of the breast (NECB) is a rare malignancy accounting for < 0.5% of breast c...
Circulating tumor DNA to add prognostic stratification beyond CA-125 in epithelial ovarian cancer.
5562 Background: Ovarian cancer has a high risk of recurrence, particularly in patients with advanced-stage disease. CA-12...
Trends over 18 months in the utilization of ctDNA monitoring assays for solid tumor patients in US clinical practice.
e23135 Background: Circulating tumor DNA (ctDNA) monitoring assays are increasingly incorporated into treatment planning,...
Efficacy and safety of venetoclax-based regimens in chronic myelomonocytic leukemia: A systematic review and meta-analysis.
e18593 Background: Chronic myelomonocytic leukemia (CMML) is a heterogeneous myelodysplastic/myeloproliferative neoplasm w...
Prognostic value and role in guiding individualized treatment of imaging extranodal extension (iENE) in nasopharyngeal carcinoma.
6078 Background: Imaging extranodal extension (iENE) is a critical prognostic factor in nasopharyngeal carcinoma (NPC). Wh...
Baseline bone marrow biopsy (BMBx) performance relative to a mastery-level standard: A SIM-BMBx interval analysis.
9046 Background: BMBx is the gold standard diagnostic test for many pathologies. Bedside BMBx is frequently performed by a...
National inpatient outcomes and hospital-volume disparities after glioma resection: A HCUP NIS analysis.
e14102 Background: High-quality glioma surgery requires multidisciplinary expertise, yet access to high-volume centers var...
Systemic inflammation and tumor immune microenvironment biomarkers (FOXP3, CD68, CD163) stratified by BRCA/HRD status in high-grade serous ovarian carcinoma: Associations with PFS and OS.
5546 Background: Outcomes in high-grade serous ovarian carcinoma (HGSOC) may be influenced by systemic inflammation and th...
Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.
5001 Background: DGC predicts overall survival (OS) benefit from DOC when added to ADT while the benefit of adding DOC to...
CT-derived visceral fat phenotypes to reveal a metabolically defined TOFI subgroup in a lung cancer screening cohort: An imaging-based framework for evaluating the BMI paradox.
8065 Background: Body mass index (BMI) imperfectly reflects metabolic health and cannot distinguish subcutaneous from visc...
Differential association of post-testosterone recovery PSA kinetics with progression and metastatic outcomes in prostate cancer.
e17122 Background: Prostate-specific antigen (PSA) kinetics following testosterone recovery from androgen deprivation ther...
Impact of RNA sequencing on diagnosis and therapy: Early results from a tertiary cancer center in India.
e23522 Background: RNA sequencing (RNA-seq) can detect gene fusions and expression-linked copy-number events that may be m...
Assessment of racial and age disparities in response and survival among acute myeloid leukemia (AML) patients treated with hypomethylating agents (HMA) and venetoclax.
e18619 Background: Venetoclax combined with an HMA has improved outcomes for older or cytotoxic chemotherapy-ineligible AM...
Global mortality and disability burden of young-onset non-colorectal gastrointestinal cancers, 1990–2021.
e16476 Background: The incidence of gastrointestinal (GI) cancers among adults younger than 50 years has risen worldwide....
Hi-C sequencing to identify clinically actionable fusions in non–small cell lung cancer missed by other sequencing technologies.
8630 Background: For a patient with non-small lung cancer (NSCLC) to benefit from targeted therapy, an actionable driver a...
Real-world utilization and survival trends of adjuvant immunotherapy in postoperative stage II-III non-small cell lung cancer: A Louisiana population-based study.
e20072 Background: Currently adjuvant immunotherapy (AI) is standard of care for patients with resectable non-small cell l...
Knowledge of HPV-related penile cancer among U.S. men: Socioeconomic differences and divergence.
e17034 Background: Human papillomavirus (HPV) is a well-established cause of penile cancer, yet awareness of this associat...
Quality of life outcomes following hypofractionated radiotherapy in locally advanced cervical cancer.
5534 Background: Cervical cancer remains a significant global health burden, particularly in low- and middle-income countr...
Association of pre-treatment hemoglobin level as a prognostic factor for survival outcomes in head and neck cancer patients treated with definitive radiation.
e18114 Background: Anemia may be associated with worse clinical outcomes in patients with head and neck squamous cell carc...
Spatial transcriptomics-guided pathology biomarker as a predictor of benefit of adjuvant docetaxel in high-risk localized prostate cancer: NRG/RTOG 0521 (NCT00288080).
5111 Background: The NRG/RTOG 0521 trial evaluated adding adjuvant docetaxel (DTX) to standard radiotherapy plus androgen...
A 3D tumorwide multi-omic atlas of intratumoral heterogeneity in <i>IDH</i> -mutant glioma.
2067 Background: Isocitrate dehydrogenase mutant (IDHmut) glioma affects over 20,000 adults per year. Treatment failure of...
Neoadjuvant antibody–drug conjugate regimens without concurrent chemotherapy versus standard chemotherapy in early HER2-positive breast cancer: A systematic review and meta-analysis of randomized trials.
e12644 Background: Standard neoadjuvant therapy for HER2-positive early breast cancer combines multi-agent chemotherapy wi...